Document is current
Any future updates will be listed below
-
Authors
Heavican-Foral, Tayla B. https://orcid.org/0000-0002-8384-6217
Korell, Felix https://orcid.org/0000-0001-7699-7212
Scarfò, Irene
Wiggers, Caroline R. M. https://orcid.org/0000-0001-6633-1468
B, Allen Thayakumar https://orcid.org/0000-0001-7664-5030
Eisenbies, Zachary
Powers, Foster https://orcid.org/0009-0000-8276-4124
Hegel, Justin https://orcid.org/0009-0004-7091-8578
Liu, Jianlin
Kulp, Steffen https://orcid.org/0009-0001-9400-690X
Silva, Harrison https://orcid.org/0000-0003-4386-0847
Wu, Gongwei https://orcid.org/0000-0002-2509-2381
Letai, Anthony https://orcid.org/0000-0002-1993-9013
Stegmaier, Kimberly https://orcid.org/0000-0003-0218-7895
Lohr, Jens G. https://orcid.org/0000-0003-3486-2445
Weinstock, David M. https://orcid.org/0000-0002-8724-3907
Maus, Marcela V. https://orcid.org/0000-0002-7578-0393
Knoechel, Birgit https://orcid.org/0000-0002-8040-0535
- License Information
-
More Information
Article History
Received: 8 October 2024
Revised: 29 May 2025
Accepted: 7 July 2025
First Online: 30 July 2025
Competing interests
: IS is an employee of ArsenalBio. AL is on the Scientific Advisory Boards of Zentalis Pharmaceuticals and Flash Therapeutics. KS is on the SAB and has stock options in Auron Therapeutics. KS receives grant funding from Novartis and KronosBio on topics unrelated to this manuscript. JGL received research funding from Bristol Myers Squibb for an unrelated project. DMW received research support from Daiichi Sankyo, AstraZeneca, Abcuro, and Secura for unrelated projects and is now an employee of Merck/MSD. M.V.M. has received research support from Kite Pharma, Servier, and Novartis for unrelated projects, is a member of the Board of Directors of 2SeventyBio, and has served as a consultant for WindMIL, Tmunity, TCR2, Sanofi, Novartis, Neximmune, Micromedicine/BendBio, Kite Pharma, Intellia, In8bio, CRISPR Therapeutics, Cabaletta Bio, BMS, Bayer, AzstraZeneca, Astellas, Arcellx, Adaptimmune, Agenus, and Allogene; none of these are related to the work herein. AZD5991 was provided by AstraZeneca. The other authors declared no relevant conflicts of interest.
: All methods were performed in accordance with the relevant guidelines and regulations. Vertebrate animal work was performed according to Dana-Farber Cancer Institute’s IACUC-approved protocol #13–034 or Massachusetts General Hospital’s IACUC-approved protocol #2020N000114.
